Published in PLoS One on December 20, 2012
Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS One (2014) 1.45
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. PLoS One (2015) 0.82
Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model. Blood Cancer J (2014) 0.82
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. J Clin Invest (2015) 0.82
Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches. PLoS One (2014) 0.82
A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J (2013) 0.81
Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow. Leukemia (2015) 0.81
Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow. Leukemia (2015) 0.79
Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study. Biomed Res Int (2015) 0.79
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma. Leukemia (2015) 0.77
Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. Oncotarget (2016) 0.76
Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. Mol Ther Oncolytics (2016) 0.75
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice. Mol Ther Oncolytics (2016) 0.75
The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. PLoS One (2016) 0.75
Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model. Yonsei Med J (2017) 0.75
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res (2001) 6.93
The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis. Medicine (Baltimore) (1976) 5.03
Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315. Biochemistry (1968) 4.83
Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev (1972) 4.63
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
BoneJ: Free and extensible bone image analysis in ImageJ. Bone (2010) 3.91
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A (1999) 2.76
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol (1979) 2.60
Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood (1998) 2.60
Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A (1972) 2.09
Animal model of human disease. Multiple myeloma. Am J Pathol (1988) 2.08
Neoplastic development in plasma cells. Immunol Rev (2003) 1.80
Abnormal serum protein and bone destruction in transmissible mouse plasma cell neoplasm (multiple myeloma). Proc Soc Exp Biol Med (1957) 1.77
A murine model of human myeloma bone disease. Bone (1997) 1.53
Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest (2004) 1.53
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol (1974) 1.49
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol (2007) 1.33
Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer (1997) 1.30
Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood (2004) 1.29
Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther (2007) 1.28
Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev (2003) 1.27
Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A (1994) 1.17
Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol (1994) 1.14
Disseminated growth of a human multiple myeloma cell line in mice with severe combined immunodeficiency disease. Cancer Res (1993) 1.13
The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev (2003) 1.13
Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun (2004) 1.12
The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol (1993) 1.12
Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol (1995) 1.08
Myeloma cell immunoglobulin expression during in vivo growth in diffusion chambers: evidence for repetitive cycles of differentiation. J Immunol (1977) 1.03
Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res (2009) 1.03
A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer (1992) 1.03
Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. Br J Cancer (1996) 0.99
Liver metastasis of cancer facilitated by chemokine receptor CCR6. Scand J Immunol (2003) 0.97
Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse. Br J Cancer (2000) 0.96
Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A (2000) 0.96
New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor. Blood (1997) 0.93
Mouse models of human myeloma. Hematol Oncol Clin North Am (2007) 0.91
Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res (1999) 0.90
Long-term engraftment of fresh human myeloma cells in SCID mice. Blood (1992) 0.89
Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris) (1999) 0.86
Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis (2004) 0.83
Bone lesions produced by transplanted plasma-cell tumors in BALB/c mice. J Natl Cancer Inst (1962) 0.80
Plasmacytoma spleen colonization: a sensitive, quantitative in vivo assay for idiotype-specific immune suppression of MOPC-315. J Immunol Methods (1978) 0.77
Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J (2006) 3.07
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol (2009) 2.49
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 2.44
Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol (2005) 2.31
Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol (2004) 2.13
Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med (2005) 2.03
Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood (2005) 2.00
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J (2002) 2.00
Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine (2011) 1.77
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood (2005) 1.69
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
The mitochondrial protein MTP18 contributes to mitochondrial fission in mammalian cells. J Cell Sci (2005) 1.44
Antioxidants, reactive oxygen and nitrogen species, gene induction and mitochondrial function. Mol Aspects Med (2002) 1.43
Activation of Nrf2 in endothelial cells protects arteries from exhibiting a proinflammatory state. Arterioscler Thromb Vasc Biol (2009) 1.43
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol (2008) 1.42
[Implementation of guidelines for PSA testing in general practice]. Tidsskr Nor Laegeforen (2014) 1.39
Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. J Immunol (2011) 1.39
Polyphenols and glutathione synthesis regulation. Am J Clin Nutr (2005) 1.36
In vivo imaging of reactive oxygen and nitrogen species in inflammation using the luminescent probe L-012. Free Radic Biol Med (2009) 1.35
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood (2008) 1.25
Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. Immunity (2005) 1.21
Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med (2002) 1.20
Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol (2003) 1.19
Gene expression studies in kiwifruit and gene over-expression in Arabidopsis indicates that GDP-L-galactose guanyltransferase is a major control point of vitamin C biosynthesis. J Exp Bot (2009) 1.19
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood (2002) 1.15
Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol (2003) 1.13
Laminar shear stress acts as a switch to regulate divergent functions of NF-kappaB in endothelial cells. FASEB J (2007) 1.13
Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol (2004) 1.12
Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene (2002) 1.12
A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia (IRIDA). Br J Haematol (2012) 1.12
c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med (2004) 1.12
Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol (2006) 1.10
Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood (2007) 1.08
Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood (2003) 1.07
Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol (2005) 1.05
Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med (2007) 1.05
Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1 beta. Prostate (2008) 1.04
Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol (2012) 1.03
Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells. Cancer Res (2009) 1.03
Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep (2013) 1.02
Electrophilic nitro-fatty acids inhibit vascular inflammation by disrupting LPS-dependent TLR4 signalling in lipid rafts. Cardiovasc Res (2013) 1.01
Notch signaling in leukemias and lymphomas. Curr Mol Med (2008) 1.01
Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol (2007) 1.01
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. Br J Haematol (2012) 1.00
Knockdown of MTP18, a novel phosphatidylinositol 3-kinase-dependent protein, affects mitochondrial morphology and induces apoptosis. J Biol Chem (2004) 1.00
Differential expression of Na+/K+-ATPase alpha-subunits in mouse hippocampal interneurones and pyramidal cells. J Physiol (2007) 0.99
Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. Br J Haematol (2010) 0.98
Hepatic nuclear factor kappa B regulates neutrophil recruitment to the injured brain. J Neuropathol Exp Neurol (2008) 0.98
Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood (2011) 0.96
Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma. PLoS One (2012) 0.96
NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy. Am J Respir Cell Mol Biol (2012) 0.95
Retinoic acid dampens LPS-induced NF-kappaB activity: results from human monoblasts and in vivo imaging of NF-kappaB reporter mice. J Nutr Biochem (2008) 0.95
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood (2007) 0.94
Strong in vivo activation of NF-kappaB in mouse lenses by classic stressors. Invest Ophthalmol Vis Sci (2003) 0.94
A mouse C kappa-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol (2002) 0.93
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood (2003) 0.93
MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol (2004) 0.93
Activating CD94:NKG2C and inhibitory CD94:NKG2A receptors are expressed by distinct subsets of committed CD8+ TCR alphabeta lymphocytes. Eur J Immunol (2004) 0.93
Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther (2004) 0.93
Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus. Eur J Immunol (2014) 0.93
Expression of inhibitory KIR is confined to CD8+ effector T cells and limits their proliferative capacity. Eur J Immunol (2004) 0.92
Mitochondrial DNA toxicity in forebrain neurons causes apoptosis, neurodegeneration, and impaired behavior. Mol Cell Biol (2010) 0.92
TLR3-responsive, XCR1+, CD141(BDCA-3)+/CD8α+-equivalent dendritic cells uncovered in healthy and simian immunodeficiency virus-infected rhesus macaques. J Immunol (2014) 0.91
DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther (2006) 0.91
Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol (2004) 0.90
T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother (2004) 0.90
In vivo imaging of NF-kappaB activity during Escherichia coli-induced mammary gland infection. Cell Microbiol (2008) 0.89
Reoxygenation of hypoxic mice with 100% oxygen induces brain nuclear factor-kappa B. Pediatr Res (2005) 0.89
Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors. PLoS One (2013) 0.88
Retinoic acid inhibits in vivo interleukin-2 gene expression and T-cell activation in mice. Immunology (2008) 0.88
Vitamin A status significantly alters nuclear factor-kappaB activity assessed by in vivo imaging. FASEB J (2004) 0.88
The PXR is a drug target for chronic inflammatory liver disease. J Steroid Biochem Mol Biol (2010) 0.88
Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer (2011) 0.88
Biological aspects of angiogenesis in multiple myeloma. Int J Hematol (2011) 0.88
Synovial tissues concentrate secreted APRIL. Arthritis Res Ther (2009) 0.88
Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res (2007) 0.88
Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun (2006) 0.87
Corneal NF-kappaB activity is necessary for the retention of transparency in the cornea of UV-B-exposed transgenic reporter mice. Exp Eye Res (2005) 0.87
Cardioprotection by hypoxia-inducible factor 1 alpha transfection in skeletal muscle is dependent on haem oxygenase activity in mice. Cardiovasc Res (2009) 0.87
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells. Eur J Immunol (2014) 0.87
The cellular mechanism by which complementary Id+ and anti-Id antibodies communicate: T cells integrated into idiotypic regulation. Immunol Cell Biol (2010) 0.86
Molecular imaging of the biological effects of quercetin and quercetin-rich foods. Mech Ageing Dev (2004) 0.86
Direct presentation of a melanocyte-associated antigen in peripheral lymph nodes induces cytotoxic CD8+ T cells. Cancer Res (2008) 0.86
CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. Eur J Immunol (2010) 0.86
Expanding the versatility of phage display II: improved affinity selection of folded domains on protein VII and IX of the filamentous phage. PLoS One (2011) 0.86
Tumor cells loaded with α-galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. Immunol Lett (2013) 0.86
Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo - studies in electrophile response element transgenic mice. Mol Nutr Food Res (2010) 0.85
DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J Immunol (2013) 0.85
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L. Blood (2004) 0.85
Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Melanoma Res (2007) 0.85